| Literature DB >> 19887014 |
Kai Zhao1, Qiwen Liu, Ruisong Yu, Zhen Li, Jianyue Li, Hong Zhu, Xiao Wu, Furong Tan, Jinbin Wang, Xueming Tang.
Abstract
BACKGROUND: Swine hepatitis E virus (swHEV) is a zoonotic disease that is considered a major problem in pig production and presents a threat to human health. Elucidation of the major antigenic epitopes of swHEV is essential for the effective control of swHEV epidemics.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19887014 PMCID: PMC2780410 DOI: 10.1186/1743-422X-6-186
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Figure 1Hydrophobic analysis and secondary structure prediction of encoding proteins of swHEV11 of ORF3.
Figure 2Purity profile of synthetic HEV peptide-swHEV11 on HPLC. Column, Kromasil-C18(4.6 × 250 nm); wavelength, 220 nm; buffer A, 0.1% TFA in 100% water; buffer B, 0.1% TFA in 100% acetonitrile; flow rate, 1.0 ml/min; gradient, from 0 to 75% of solution A.
Immunoreactivity of synthetic swine HEV peptides (for IgG) with a positive serum panel and a negative serum panel
| Reference | Positive references | Quantity | Negative references | Quantity | ||
|---|---|---|---|---|---|---|
| sera | + | - | + | - | ||
| swHEV-1 | 6 | 18 | 24 | 0 | 6 | 6 |
| swHEV-2 | 17 | 7 | 24 | 3 | 3 | 6 |
| swHEV-3 | 19 | 5 | 24 | 2 | 4 | 6 |
| swHEV-4 | 4 | 20 | 24 | 0 | 6 | 6 |
| swHEV-5 | 11 | 13 | 24 | 1 | 5 | 6 |
| swHEV-6 | 6 | 18 | 24 | 0 | 6 | 6 |
| swHEV-7 | 14 | 10 | 24 | 2 | 4 | 6 |
| swHEV-8 | 8 | 16 | 24 | 0 | 6 | 6 |
| swHEV-9 | 18 | 6 | 24 | 3 | 3 | 6 |
| swHEV-10 | 13 | 11 | 24 | 1 | 5 | 6 |
| swHEV-11 | 21 | 3 | 24 | 0 | 6 | 6 |
| swHEV-12 | 21 | 3 | 24 | 2 | 4 | 6 |
+, positive; -, negative
Immunoreactivity of synthetic swine HEV peptides (for IgM) with a positive serum panel
| Reference | Positive references | Quantity | |
|---|---|---|---|
| sera | + | - | |
| swHEV-1 | 4 | 20 | 24 |
| swHEV-2 | 5 | 19 | 24 |
| swHEV-3 | 3 | 21 | 24 |
| swHEV-4 | 0 | 24 | 24 |
| swHEV-5 | 6 | 18 | 24 |
| swHEV-6 | 6 | 18 | 24 |
| swHEV-7 | 5 | 19 | 24 |
| swHEV-8 | 5 | 19 | 24 |
| swHEV-9 | 3 | 21 | 24 |
+, positive; -, negative
Reproducibility of the peptide-based ELISA kits(Anti-HEV IgG kit)
| Serum | Intro-batcha | Inter-batchb | ||||
|---|---|---|---|---|---|---|
| X | CV | X | CV | |||
| 1 | 0.382 | 0.0209 | 5.5% | 0.387 | 0.0475 | 12.3% |
| 2 | 0.299 | 0.0215 | 7.2% | 0.327 | 0.0468 | 14.3% |
| 3 | 0.227 | 0.0134 | 5.9% | 0.274 | 0.0223 | 8.2% |
| 4 | 0.356 | 0.0152 | 4.3% | 0.382 | 0.0423 | 11.1% |
| 5 | 0.329 | 0.0185 | 5.6% | 0.395 | 0.0450 | 10.4% |
| 6 | 0.333 | 0.0163 | 4.9% | 0.381 | 0.0670 | 17.7% |
X, mean OD values; SD., standard deviation;
CV, coefficient of variation.
a The intro-batch duplicateivity test
b The inter-batch duplicativity test
Comparison between the synthetic peptide-based and recombinant-based kits a for anti-HEV IgG test
| Recombinant-based kita | Peptide-based kit | ||
|---|---|---|---|
| Subtotal | |||
| + | - | ||
| + | 64 | 24 | 88 |
| - | 1 | 5 | 6 |
| Total | 94 | ||
+, positive; -, negative.
a From Beijing WANTAI Biological Pharmacy
Enterprise Co., Ltd.
Comparison between the synthetic peptide-based and recombinant-based kits a for anti-HEV IgM test
| Recombinant-based kita | Peptide-based kit | ||
|---|---|---|---|
| + | - | ||
| + | 29 | 59 | 88 |
| - | 1 | 5 | 6 |
| Total | 94 | ||
+, positive; -, negative.
a From Beijing WANTAI Biological Pharmacy
Enterprise Co., Ltd.
Comparison between the KHB kit and recombinant-based kitsa
| Recombinant-based kit a | KHB | kit b | Subtotal |
|---|---|---|---|
| + | - | ||
| + | 50 | 38 | 88 |
| - | 5 | 6 | |
| Total | 1 | 94 | |
+, positive; -, negative.
a From Beijing WANTAI Biological Pharmacy
Enterprise Co., Ltd.
b From Shanghai Kehua Bio-Engineering Co., Ltd.
Comparison between the synthetic peptide-based and KHB kit for anti-HEV IgG test
| + | - | ||
|---|---|---|---|
| + | 40 | 48 | 88 |
| - | 1 | 5 | 6 |
| Total | 94 | ||
+, positive; -, negative.
b From Shanghai Kehua Bio-Engineering
Co., Ltd.
Amino acid sequence of each of the 12 peptides swHEV-1,2,3,4,5,6,7,8,9,10,11,12
| Peptides | Sequence | Position |
|---|---|---|
| ORF1 | ||
| swHEV1 | AGRCLEVGAHPRSINDNPNVLHRCFLKPVG RDVQRWYTAPTRGPAANCRRSALRGLPP | 83-140 |
| swHEV2 | VEHNPKRLEAAYRETCSRRGTAAYPLLGA | 874-925 |
| swHEV3 | SDSVLTFELTDIVHCRMAAPSQRKAVLSTL | 1295-1346 |
| swHEV4 | ESLRGFWKKHSGEPGTLLWNTVWNMAVIAHC | 1521-1582 |
| ORF2 | ||
| swHEV5 | PRQPARPLGSAWRDQSQRPAASTRRRPAPAGA | 90-153 |
| swHEV6 | AQQDKGIAIPHDIDLGESRVVIQDYDNQ | 433-476 |
| swHEV7 | PVSISAVGVLAPHSALAILEDTADYPAR AHTFDDFCPECRSLGLQGC | 606-653 |
| ORF3 | ||
| swHEV8 | CPRHRPVSPLAVAAGGAAAVPAVVSGV | 22-58 |
| swHEV9 | SPSPSPIFIQPTPSHLTFQPQPGLELALGSQ | 55-112 |
| swHEV10 | LALGSQPVHSAPLGATSPSAPPLPPVVD | 79-114 |
| swHEV11 | LGATSPSAPPLPPVVDLPQLGLRR | 91-114 |
| swHEV12 | LALGSQPVHSAPLGATSPSAPPL | 79-101 |